Alzheimer’s disease stands apart from other forms of dementia because of what happens inside the brain at the cellular level: amyloid-beta proteins accumulate into plaques while tau proteins tangle into knots, and these two specific pathologies are the hallmark signature of Alzheimer’s. Under a microscope, a pathologist examining brain tissue from someone with Alzheimer’s will see these characteristic plaques and tangles; examine the brain of someone with frontotemporal dementia or Lewy body dementia, and the damage looks fundamentally different. This distinction matters because it explains why Alzheimer’s progresses the way it does, why it typically starts with memory problems, and why treatments developed for Alzheimer’s may not work for other dementias.
Alzheimer’s accounts for 60 to 80 percent of all dementia cases, making it by far the most common form. But prevalence does not mean it is the only form, or even that it is always correctly diagnosed. Many people are told they have Alzheimer’s when the actual cause of their cognitive decline is vascular dementia from small strokes, Lewy body dementia with its distinctive hallucinations, or frontotemporal dementia destroying personality and behavior first. The differences between these conditions are not academic—they affect which medications might help, how quickly someone is likely to decline, and what family members should expect.
Table of Contents
- How Does the Brain Damage of Alzheimer’s Differ From Vascular and Frontotemporal Dementia?
- Why Early Symptoms in Alzheimer’s Differ From Other Dementias, and What That Means for Diagnosis
- Progression Speed and Life Expectancy: How Alzheimer’s Compares to Other Forms
- Treatment Approaches: Why Medications Work Differently Across Dementia Types
- Behavioral and Psychological Changes: Where the Dementias Diverge
- Family and Caregiver Experience Across Dementia Types
- Genetic Risk and Predictability: What We Know and Don’t Know
- Frequently Asked Questions
How Does the Brain Damage of Alzheimer’s Differ From Vascular and Frontotemporal Dementia?
Alzheimer’s causes damage through protein misfolding and accumulation. The amyloid-beta plaques build up outside brain cells and disrupt communication between neurons; the tau tangles form inside cells and choke off their ability to function. This damage begins in the hippocampus, the brain region critical for memory formation, which is why most people with Alzheimer’s notice memory loss first—they forget recent conversations, appointments, or where they placed their keys, yet may remember events from decades ago. Vascular dementia works completely differently. It results from reduced blood flow to the brain, typically due to a series of small strokes. The damage is stepwise rather than gradual: a person might function normally, then after a stroke suffer a sudden, noticeable decline in thinking, then plateau for months until another stroke causes another drop.
A person with vascular dementia might retain their memory reasonably well while losing the ability to plan or organize—a different profile than Alzheimer’s. Frontotemporal dementia targets the front and side regions of the brain, areas responsible for personality, judgment, and language. Someone with frontotemporal dementia often experiences dramatic personality changes—becoming impulsive, withdrawn, or inappropriately blunt—while memory remains relatively preserved until late stages. Imaging and autopsy studies confirm these differences. An MRI of an Alzheimer’s brain typically shows shrinkage in the hippocampus and temporal lobes; a vascular dementia brain shows evidence of multiple small infarcts or white matter damage from chronic reduced blood flow; a frontotemporal dementia brain shows atrophy concentrated in the frontal and anterior temporal lobes. These patterns help doctors distinguish between conditions, though diagnosis during life remains imperfect.
Why Early Symptoms in Alzheimer’s Differ From Other Dementias, and What That Means for Diagnosis
Alzheimer’s nearly always announces itself through memory problems. A spouse notices that their partner is asking the same question repeatedly; a person forgets the names of grandchildren they see regularly; someone gets lost in a familiar neighborhood. These memory lapses often begin subtly and gradually worsen over months or years before other thinking problems emerge. This progression is so typical that doctors consider early memory loss one of the most reliable clues. Lewy body dementia, the second most common type after Alzheimer’s, presents with a strikingly different calling card: hallucinations. people see detailed, realistic figures—often animals or people—that others cannot see.
They may also have parkinsonian symptoms: rigidity, tremor, shuffling gait. Memory loss in Lewy body dementia occurs, but it is often less severe than in Alzheimer’s. A critical limitation in diagnosing Lewy body dementia is that hallucinations can be misinterpreted as psychiatric symptoms and incorrectly treated with antipsychotic drugs, which can be harmful in this condition and accelerate decline. The danger of misdiagnosis is real. A person with early Lewy body dementia who is hallucinating might see a psychiatrist first and receive a diagnosis of schizophrenia or bipolar disorder, delaying the correct diagnosis by years. Someone with early frontotemporal dementia might be labeled with depression or personality disorder when the true cause is progressive brain damage. Primary care doctors see dementia less frequently than specialists, so distinguishing between types based on symptom presentation alone is genuinely difficult, even for experienced clinicians.
Progression Speed and Life Expectancy: How Alzheimer’s Compares to Other Forms
Alzheimer’s typically progresses over 8 to 12 years from diagnosis to death, though the range is wide—some people decline over 5 years, others over 20. The progression follows a recognizable arc: gradual memory loss, then expanding cognitive problems, then eventually loss of speech and the ability to walk or eat. This relatively slow progression is one reason Alzheimer’s research can continue for years and families have time to plan, though the psychological weight of watching someone decline so gradually over a decade is its own burden. Vascular dementia progression depends on the timing of strokes.
If strokes are frequent and involve large blood vessels, decline can be rapid; if they are small and infrequent, someone may live for many years with vascular dementia and die of an unrelated cause. This unpredictability makes it harder for families to plan. Lewy body dementia tends to progress faster than Alzheimer’s on average—often 5 to 8 years—and the presence of both hallucinations and parkinsonian symptoms means people are more likely to fall, which introduces serious complications. Frontotemporal dementia varies widely in speed, but many people decline more rapidly than those with Alzheimer’s, particularly in the behavioral variant where judgment collapses quickly.
Treatment Approaches: Why Medications Work Differently Across Dementia Types
Alzheimer’s-specific medications attempt to preserve acetylcholine, a neurotransmitter that declines in Alzheimer’s, or to slow the accumulation of amyloid. Donepezil, rivastigmine, and galantamine are cholinesterase inhibitors; memantine works through a different mechanism on glutamate. These medications do not reverse Alzheimer’s or stop it entirely—they may slow decline by a few months at best—but they represent the only disease-modifying options currently available for Alzheimer’s specifically. More recently, monoclonal antibodies that target amyloid, like aducanumab and lecanemab, have shown modest effects in early Alzheimer’s disease, though they carry risks of amyloid-related imaging abnormalities (ARIA).
These Alzheimer’s medications do not work for Lewy body dementia or frontotemporal dementia, and antipsychotic drugs used to manage hallucinations in Lewy body dementia can be dangerous in ways they are not in Alzheimer’s. Vascular dementia is primarily managed by controlling stroke risk factors—blood pressure, cholesterol, diabetes—not by medications targeting dementia pathology. Frontotemporal dementia has no disease-modifying medications; treatment focuses on managing behavior and language problems with selective serotonin reuptake inhibitors or other drugs chosen for specific symptoms. The comparison is sobering: Alzheimer’s at least has targeted, if limited, pharmaceutical options; other dementias rely largely on symptom management.
Behavioral and Psychological Changes: Where the Dementias Diverge
Behavioral problems occur in all dementias, but their character and timing differ. In Alzheimer’s, behavioral changes typically emerge after significant cognitive decline. A person who was calm throughout their mild cognitive impairment may become agitated, anxious, or depressed as memory and thinking decline. Sundowning—confusion and restlessness in the evening—is common in Alzheimer’s. Aggression can occur, usually triggered by frustration, fear, or unmet physical needs. In frontotemporal dementia, behavior is often the leading problem. People may become disinhibited and inappropriate—making crude jokes, spending money recklessly, or showing no concern for family.
Others become apathetic and withdrawn, losing all motivation and initiative. These changes reflect damage to brain regions governing impulse control and emotional regulation, and they often devastate family members because the person’s personality seems to have been replaced. A warning here is that frontotemporal dementia is often missed or misdiagnosed as a psychiatric condition because the behavioral changes are so prominent and the person may seem cognitively intact at first. Lewy body dementia brings distinctive features: vivid hallucinations, often frightening or elaborate, and fluctuating awareness—a person may be clear one hour and confused the next. Depression is common and can be severe. The combination of hallucinations, parkinsonism, and cognitive problems creates a particularly challenging clinical picture. Antipsychotics, which are sometimes used to treat hallucinations in other dementias, worsen Lewy body dementia and can trigger neuroleptic malignant syndrome, a life-threatening emergency.
Family and Caregiver Experience Across Dementia Types
The day-to-day experience of caring for someone with Alzheimer’s differs from caring for someone with frontotemporal dementia. The Alzheimer’s caregiver often manages gradual memory loss, repetition, getting lost, and eventually total dependence in daily activities. The person usually remains emotionally connected; they may not remember your name, but they often recognize your face and feel your presence.
A frontotemporal dementia caregiver faces someone whose personality has changed while they remain relatively independent physically. A person might refuse help, show callousness toward family, or engage in risky behavior that the caregiver must prevent. The loss of personality, while the body remains strong and mobile, creates a wrenching dynamic where the caregiver is mourning someone who is still physically present. Support groups for Alzheimer’s caregivers and frontotemporal dementia caregivers have different tones and focuses precisely because the challenges are distinct.
Genetic Risk and Predictability: What We Know and Don’t Know
Apolipoprotein E (APOE) is a well-established genetic risk factor for Alzheimer’s disease. People who carry two copies of the APOE ε4 allele have higher risk; those with one copy have moderately elevated risk; those with no copies have lower risk. Yet APOE ε4 is neither necessary nor sufficient for Alzheimer’s—many people with two copies live into their 80s or 90s without dementia, while some people without the allele develop Alzheimer’s. Genetic testing for APOE can inform risk but cannot predict who will develop disease or when.
Frontotemporal dementia has a stronger genetic component than Alzheimer’s in some cases: mutations in genes like C9orf72, GRN, and MAPT account for about 10 to 15 percent of cases. Families with known mutations face more concrete risk stratification, though again, carrying a mutation does not guarantee disease or determine age of onset. Vascular dementia has genetic influences through conditions like hypertension and hyperlipidemia, but it is more a product of lifestyle and medical management than inherited destiny. Lewy body dementia appears to have modest genetic contributions, but inheritance patterns are less well understood than in Alzheimer’s or familial frontotemporal dementia. The practical implication is that genetic counseling and testing have real value in families with strong dementia histories, particularly when frontotemporal dementia is present, but predictive testing for Alzheimer’s based on APOE alone remains controversial and often unhelpful for decision-making.
- —
Frequently Asked Questions
Can someone have more than one type of dementia at the same time?
Yes. Mixed pathology is common, especially in people who are very old. Someone might have Alzheimer’s changes plus vascular damage, or Lewy body pathology combined with Alzheimer’s. These mixed cases can be harder to diagnose and predict during life, and symptoms may reflect contributions from multiple pathologies. Autopsy studies show that pure single-pathology dementia is less common than previously thought.
How do doctors tell the difference between these dementias if diagnosis is uncertain during life?
Doctors use clinical evaluation (detailed history and symptoms), neuropsychological testing (specific cognitive profiles), MRI or PET imaging, and sometimes cerebrospinal fluid biomarkers or blood biomarkers. No single test is definitive. A neurologist or geriatric psychiatrist with dementia expertise can narrow the diagnosis, but certainty often requires autopsy examination of brain tissue, which is why living diagnosis remains probabilistic.
Is Alzheimer’s preventable or reversible?
Alzheimer’s cannot be reversed once it begins. It may be slowed by disease-modifying medications if caught very early, and cognitive decline may be delayed by management of vascular risk factors (blood pressure, cholesterol, diabetes), cognitive engagement, physical exercise, quality sleep, and social connection. Prevention remains an area of active research, but no intervention has been proven to prevent Alzheimer’s with certainty.
If someone has hallucinations, do they definitely have Lewy body dementia?
No. Hallucinations can occur in Alzheimer’s, frontotemporal dementia, and other conditions, particularly in late stages or with delirium from infection or medication. However, vivid, detailed, recurrent hallucinations early in the illness are much more suggestive of Lewy body dementia. The presence of parkinsonian features alongside hallucinations and cognitive problems strengthens the case for Lewy body dementia.
Can vascular dementia be stopped if I manage my stroke risk factors now?
Managing stroke risk factors—controlling blood pressure, treating diabetes, managing cholesterol, not smoking, staying physically active—can prevent future strokes and slow vascular dementia progression. If vascular dementia has already begun, these measures can prevent additional strokes and further cognitive decline, but they cannot reverse damage from strokes that have already occurred. —
